Sign in
Not yet taking people in United StatesNo phase

Comparing Safety of Two Stem Cell Transplant Types in Leukemia and Myelodysplastic Syndrome

Compares transplant safety between two graft types in people with leukemia or myelodysplastic syndrome.

Key facts

Who runs it
Miltenyi Biomedicine GmbH
Where
New York, United StatesSee the site
Trial code
Registry title
PRAISE-IR Versus CIBMTR Controls
Status
Not yet recruiting
People taking part
51 people, planned
Started
31 Jul 2026
Planned end
30 Sept 2026
Type of study
Observational, 4 groups
Record updated
28 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial compares people who had a CD34-selected donor stem cell transplant for AML, MDS or ALL with a control group from a transplant registry. All were in complete remission at transplant.

Age
1 year to under 66 years at the time of transplant.
Sex
All sexes can join.
Disease stage
AML, MDS or ALL, in morphologic complete remission at the time of the donor stem cell transplant.
Earlier treatment
First donor stem cell transplant (in the US between 2021 and 2023 for the registry groups), with strong (myeloablative) conditioning before it. Donor must be a fully matched (8/8) related or unrelated donor.
Biomarker or test result
HLA 8/8 tissue type donor (related or unrelated).

Main reasons for not taking part

  • Donor tissue type less than 8/8 (for the PRAISE-IR group)
  • Did not sign consent for research (registry groups)
  • Transplanted at a center that does not meet registry data quality standards
  • Took part in the PRAISE-IR study (for the registry CD34-selection group)
  • Control group: used ATG, alemtuzumab or ex vivo CD34 selection

The registry criteria, word for word

Show all 50 criteriaShow less

Who can take part

  • Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)
  • Patients who participated in the PRAISE-IR single center phase II study
  • Patient age at transplant: ≥ 1 year and < 66 years
  • HLA 8/8 MRD or MUD
  • Conditioning intensity: myeloablative
  • Conditioning regimens: Model-based ATG with TBI/Thiotepa/Cyclophospamide (TBI/Thio/Cy) or Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu)
  • Morphologic complete remission at the time of alloHCT Arm B: Standard ATG dosing CD34-selection (CIBMTR population)
  • First AlloHCT in the US between 2021-2023
  • Patient age at transplant: ≥ 1 year and < 66 years
  • Disease: Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell allograft
  • Conditioning intensity: myeloablative conditioning
  • Conditioning regimens: standard dose ATG (2.5 mg/kg/day given on Day -4 and Day -3)
  • GVHD prophylaxis: ex vivo CD34 selection
  • Morphologic complete remission at the time of alloHCT Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)
  • Patients in BMT CTN 1301, who received the CD34-selected graft
  • Patient age at transplant: ≥ 1 year and < 66 years
  • Disease:Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell allograft
  • Conditioning intensity: myeloablative conditioning
  • Conditoning regmens: TBI/Thiotepa/Cyclophospamide (TBI/Thio/Cy) or Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) and standard dose ATG (2.5 mg/kg/day given on Day -4 and Day -3)
  • GVHD prophylaxis: ex vivo CD34 selection
  • Morphologic complete remission at the time of alloHCT Arm C: Control CIBMTR population
  • First AlloHCT in the US between 2021-2023
  • Patient age at transplant: ≥ 1 year and < 66 years
  • Disease:Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell
  • Conditioning intensity: myeloablative conditioning
  • Conditioning regimens: Busulfan/Cyclophosphamide (Bu/Cy), Busulfan/Fludaranbine (Bu/Flu), Cyclophosphamide/TBI (Cy/TBI), TBI/Etopsoside
  • GVHD prophyalxis: / CNI or PTCy-based
  • CNI-based: CNI (tacrolimus or ciclosporin) plus MTX
  • PTCy-based: Cyclophosphamide on day +3 and +4 (50 mg/kg/d) combined with CNI and mycophenolate mofetil (MMF)

Who cannot take part

  • Patients who received PTCy with sirolimus (and not a CNI)
  • Patients will be entered into this trial only if they meet none of the following criteria:
  • Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)
  • HLA <8/8 MRD or MUD Arm B: Standard ATG dosing CD34-selection (CIBMTR population)
  • Patients who participated in the PRAISE-IR study
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of CNI-(Tac/MTX) or PTCy-based GVHD prophylaxis Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of CNI- or PTCy-based GVHD prophylaxis Arm C: Control CIBMTR population
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of ATG and/or alemtuzumab
  • Use of ex vivo CD34 selection

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 66 years old?

Where in United States

  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Michaela MalchowNot yet recruiting

About the trial

What the trial wants to find out

The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.

The 4 groups in the trial

  • Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)

    CliniMACS CD34 Reagent System

  • Arm B: Standard ATG dosing CD34-selection (CIBMTR population)

    Intervention: CliniMACS CD34 Reagent System

  • Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)

    CliniMACS CD34 Reagent System

  • Arm C: Control CIBMTR population

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison of the PRAISE -IR ("Phase 2 Study of Personalized r-ATG (Rabbit Anti-thymocyte Globulin) Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (Hematopoietic Cell Transplantation) ", NCT04872595) Study Population With CIBMTR Controls
Plain-language title
Comparing Safety of Two Stem Cell Transplant Types in Leukemia and Myelodysplastic SyndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07717164, who can take part
Record updated
28 July 2026